Lipid Abnormalities and Hypertension

  • Thomas D. Giles
Part of the Current Clinical Practice book series (CCP)


Abnormalities of blood lipids constitute one of the more common risk factors for cardiovascular disease that coexist with systemic arterial hypertension (Table 33-1). Hypertension and lipid disturbances may be part of a genetic abnormality, the Familial Dyslipidemic Syndrome, which is found in approx 12% of people with hypertension and in approx 50% of those with early familial hypertension, increased LDL cholesterol, and triglycerides. Thus, it is often necessary to consider the additional cardiovascular risk associated with dyslipidemia when planning a therapeutic strategy for hypertensive patients.


Total Serum Cholesterol National Cholesterol Education Program Lipid Abnormality Scandinavian Simvastatin Survival Study Systemic Arterial Hypertension 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Readings

  1. Fuster V, Badimon L, et al. (1992) The pathogenesis of coronary artery disease and the acute coronary syndrome. N Engl J Med 326: 242–250.PubMedCrossRefGoogle Scholar
  2. Fuster V, et al. (1992) The pathogenesis of coronary artery disease and the acute coronary syndrome (second of two parts). N Engl J Med 326: 310–318.PubMedCrossRefGoogle Scholar
  3. Giles TD (1997) Lipid factors in the hypertension syndrome. J Cardiovasc Risk 4: 257–259.PubMedCrossRefGoogle Scholar
  4. Grundy SM (1995) Role of low-density lipoproteins in atherogenesis and development of coronary heart disease. Clin Chem 41: 139–146.PubMedGoogle Scholar
  5. Malloy MJ, Kane JP (1998) Aggressive medical therapy for the prevention and treatment of coronary artery disease. Disease-A-Month 44: 1–40.PubMedCrossRefGoogle Scholar
  6. Reaven GM, Lithell H, Landsberg L (1996) Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system. NEngl J Med 334: 374–381.CrossRefGoogle Scholar
  7. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with Coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389.Google Scholar
  8. Shepard J, Cobbe SM, Ford I, et al. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301–1307.CrossRefGoogle Scholar
  9. Stary HC (1989) Evolution and progression of astherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis 9: 119–132.Google Scholar
  10. Williams RR, Hunt SC, Hopkins PN, Stults BM, Wu LL, Hasstedt SJ (1988) Familial dyslipidemic hypertension: evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA 259: 3579–3596.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Thomas D. Giles

There are no affiliations available

Personalised recommendations